 |
51 Diseases |  |
15 Trials |
|
15 Trials |  |
1554 News |  |
| «12...6789101112131415161718 |
- New trial, Adverse events: BEEP2b: Characterization of Epilepsy Patients BEEP 2b (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=12, Not yet recruiting, Sponsor: Food and Drug Administration (FDA)
- | carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
New P4 trial: Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures (clinicaltrials.gov) - Mar 11, 2016
P4, N=75, Not yet recruiting, Sponsor: All India Institute of Medical Sciences, Bhubaneswar
- sodium valproate / Generic mfg., oxcarbazepine / Generic mfg.
Trial completion: VIRIDAE: Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=30, Completed, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed
- | levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Enrollment closed, Enrollment change: Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) (clinicaltrials.gov) - Jan 12, 2016
P3, N=78, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=300 --> 78
- oxcarbazepine / Generic mfg.
Trial completion: Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder (clinicaltrials.gov) - Dec 21, 2015
P4, N=50, Completed, Sponsor: All India Institute of Medical Sciences, Bhubaneswar
Recruiting --> Active, not recruiting | N=300 --> 78 Recruiting --> Completed
- oxcarbazepine / Generic mfg.
Trial completion: Intervention Study for Individuals With Compulsive Sexual Behavior (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=135, Completed, Sponsor: University of Sao Paulo General Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- sodium valproate / Generic mfg., oxcarbazepine / Generic mfg.
New trial: VIRIDAE: Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: University Hospital, Rouen
- |||| oxcarbazepine / Generic mfg.
Enrollment open, Trial initiation date: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Aug 24, 2015
P2, N=60, Recruiting, Sponsor: Queen Mary University of London
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Oct 2014
- oxcarbazepine / Generic mfg.
Enrollment open: Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder (clinicaltrials.gov) - Jun 28, 2015
P4, N=50, Recruiting, Sponsor: All India Institute of Medical Sciences, Bhubaneswar
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- ||||| everolimus / Generic mfg.
Enrollment closed: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Jun 18, 2015
P3, N=326, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Trial primary completion date: Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) (clinicaltrials.gov) - Jun 11, 2015
P3, N=300, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Apr 2016
- oxcarbazepine / Generic mfg.
New P4 trial: Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder (clinicaltrials.gov) - May 29, 2015
P4, N=50, Not yet recruiting, Sponsor: All India Institute of Medical Sciences, Bhubaneswar
- carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Trial completion: Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine. (clinicaltrials.gov) - Apr 22, 2015
P4, N=10, Completed, Sponsor: Odense University Hospital
Trial primary completion date: Jul 2015 --> Apr 2016 Active, not recruiting --> Completed
- |||||||||| New P3 trial, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Mar 2, 2015
P3, N=2000, Recruiting, Sponsor: Hannover Medical School
- |||| everolimus / Generic mfg.
Trial primary completion date: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Feb 27, 2015
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Sep 2016
- morphine sulphate / Generic mfg., oxcarbazepine / Generic mfg.
Trial primary completion date: Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain (clinicaltrials.gov) - Dec 13, 2014
P1, N=12, Recruiting, Sponsor: Indiana University
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Nov 2014 --> Nov 2016
- ||| oxcarbazepine / Generic mfg.
Clinical: Intervention Study for Individuals With Compulsive Sexual Behavior (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=135, Active, not recruiting, Sponsor: University of Sao Paulo General Hospital
- pregabalin / Generic mfg., oxcarbazepine / Generic mfg.
Trial completion: Symptom Based Treatment of Neuropathic Pain (clinicaltrials.gov) - Aug 21, 2014
P4, N=63, Completed, Sponsor: Ju Seok Ryu
Trial primary completion date: Nov 2014 --> Nov 2016 Recruiting --> Completed
- Clinical: Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study (clinicaltrials.gov) - Aug 18, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Children's Hospital Boston
- levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Trial completion, Monotherapy: Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (clinicaltrials.gov) - Aug 1, 2014
P4, N=353, Completed, Sponsor: UCB Korea Co. Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- | pregabalin / Generic mfg., oxcarbazepine / Generic mfg.
New P4 trial: Symptom Based Treatment of Neuropathic Pain (clinicaltrials.gov) - Jul 4, 2014
P4, N=63, Recruiting, Sponsor: Ju Seok Ryu
- oxcarbazepine / Generic mfg.
Trial primary completion date: IMIOXC: Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain (clinicaltrials.gov) - May 1, 2014
P4, N=117, Completed, Sponsor: Søren H. Sindrup
Active, not recruiting --> Completed Trial primary completion date: Mar 2013 --> May 2013
- oxcarbazepine / Generic mfg.
Trial completion date: IMIOXC: Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain (clinicaltrials.gov) - May 1, 2014
P4, N=117, Completed, Sponsor: Søren H. Sindrup
Trial primary completion date: Mar 2013 --> May 2013 Trial completion date: Dec 2013 --> May 2013
- oxcarbazepine / Generic mfg.
Trial completion: IMIOXC: Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain (clinicaltrials.gov) - May 1, 2014
P4, N=117, Completed, Sponsor: Søren H. Sindrup
Trial completion date: Dec 2013 --> May 2013 Recruiting --> Completed
- | levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Enrollment open: Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) (clinicaltrials.gov) - Apr 29, 2014
P3, N=300, Recruiting, Sponsor: Emory University
Recruiting --> Completed Not yet recruiting --> Recruiting
- | oxcarbazepine / Generic mfg.
New P2 trial: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Apr 2, 2014
P2, N=60, Not yet recruiting, Sponsor: Queen Mary University of London
- rufinamide / Generic mfg., oxcarbazepine / Generic mfg.
Trial completion: Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study (clinicaltrials.gov) - Mar 13, 2014
P4, N=24, Completed, Sponsor: University of Zurich
Not yet recruiting --> Recruiting Recruiting --> Completed
- morphine sulphate / Generic mfg., oxcarbazepine / Generic mfg.
New P1 trial: Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain (clinicaltrials.gov) - Mar 3, 2014
P1, N=12, Recruiting, Sponsor: Indiana University
- Trial initiation date: Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania (clinicaltrials.gov) - Jan 16, 2014
P4, N=120, Recruiting, Sponsor: Guiyun Xu
Recruiting --> Completed Initiation date: Jun 2013 --> Sep 2013
- Enrollment change: Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania (clinicaltrials.gov) - Jan 16, 2014
P4, N=120, Recruiting, Sponsor: Guiyun Xu
Initiation date: Jun 2013 --> Sep 2013 N=480 --> 120
- ||||| oxcarbazepine / Generic mfg.
Enrollment change: Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures (clinicaltrials.gov) - Dec 5, 2013
P2/3, N=99, Completed, Sponsor: Novartis Pharmaceuticals
N=480 --> 120 N=200 --> 99
- ||||||| oxcarbazepine / Generic mfg.
Trial completion: Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures (clinicaltrials.gov) - Dec 5, 2013
P2/3, N=99, Completed, Sponsor: Novartis Pharmaceuticals
N=200 --> 99 Active, not recruiting --> Completed
- | oxcarbazepine / Generic mfg.
Enrollment closed: Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures (clinicaltrials.gov) - Oct 27, 2013
P2/3, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- topotecan / Generic mfg., temozolomide / Generic mfg.
Trial completion: Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas (clinicaltrials.gov) - Oct 22, 2013
P1, N=62, Completed, Sponsor: Katy Peters
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Enrollment closed, Monotherapy: Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (clinicaltrials.gov) - Aug 4, 2013
P4, N=353, Active, not recruiting, Sponsor: UCB Korea Co. Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | New P4 trial: Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania (clinicaltrials.gov) - Jul 4, 2013
P4, N=120, Recruiting, Sponsor: Guiyun Xu
- || levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
New P3 trial: Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) (clinicaltrials.gov) - Jul 1, 2013
P3, N=300, Recruiting, Sponsor: Emory University
- oxcarbazepine / Generic mfg.
Trial completion: Oxcarbazepine Versus Placebo in Childhood Autism (clinicaltrials.gov) - Mar 25, 2013
P=N/A, N=5, Completed, Sponsor: University of Medicine and Dentistry New Jersey
Recruiting --> Active, not recruiting Terminated --> Completed
- ||| oxcarbazepine / Generic mfg.
Trial completion, HEOR: ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=225, Completed, Sponsor: Desitin Arzneimittel GmbH
Terminated --> Completed Active, not recruiting --> Completed
- temozolomide / Generic mfg., dasatinib / Generic mfg.
Enrollment change: Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma (clinicaltrials.gov) - Nov 19, 2012
P1, N=0, Withdrawn, Sponsor: Annick Desjardins
Active, not recruiting --> Completed N=48 --> 0
- || everolimus / Generic mfg.
New P3 trial: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Oct 23, 2012
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| oxcarbazepine / Generic mfg.
New P1 trial: Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions (clinicaltrials.gov) - Oct 8, 2012
P1, N=59, Completed, Sponsor: Roxane Laboratories
- ||| oxcarbazepine / Generic mfg.
New P1 trial: Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions (clinicaltrials.gov) - Oct 4, 2012
P1, N=64, Completed, Sponsor: Roxane Laboratories
- | Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
New P1 trial: Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers (clinicaltrials.gov) - Sep 3, 2012
P1, N=11, Completed, Sponsor: Bial - Portela C S.A.
- | Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
New P1 trial: Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers (clinicaltrials.gov) - Sep 3, 2012
P1, N=12, Completed, Sponsor: Bial - Portela C S.A.
- CINelim (terameprocol) / Erimos Pharma
Enrollment change: Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (clinicaltrials.gov) - Apr 30, 2012
P1/2, N=35, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=48 --> 0 N=50 --> 35
- | oxcarbazepine / Generic mfg.
Enrollment change: Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures (clinicaltrials.gov) - Apr 22, 2012
P2/3, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=50 --> 35 N=170 --> 50
- | levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
New P4 trial, Monotherapy: Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (clinicaltrials.gov) - Dec 21, 2011
P4, N=353, Active, not recruiting, Sponsor: UCB Korea Co. Ltd.